Compare Firy Inc. (FIRY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Firy Inc. trades at $11.27 (market cap $206.28M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 23.7× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FIRY | TVTX | |
|---|---|---|
Market Cap | $206.28M | $4.88B |
Volume | 112,784 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $13.10 | $67.52 |
52-Week Low | $2.28 | $26.79 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $174.88M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.41, up 0.16% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0M but posted a net loss of -$70.41M for 2025, with negative cash flow of -$86.41M. Recent developments include a $719M legal victory and board appointment of Marc Lasry. Valuation metrics show P/S of 1.65 and P/B of 2.44, while profitability remains challenged with -60.23% net margin.
Despite technical strength, FIRY faces significant fundamental challenges with persistent losses and cash burn. The legal win provides potential upside but collection uncertainty remains. Analyst consensus is mixed with 20% buy, 60% hold ratings. Investment appeal hinges on successful monetization of legal judgment and operational turnaround amid ongoing cash flow concerns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
